首页|抗血管内皮生长因子与地塞米松玻璃体腔植入剂起始联合应用对视网膜中央静脉阻塞黄斑水肿外层视网膜结构完整性变化的长期观察

抗血管内皮生长因子与地塞米松玻璃体腔植入剂起始联合应用对视网膜中央静脉阻塞黄斑水肿外层视网膜结构完整性变化的长期观察

扫码查看
目的 观察抗血管内皮生长因子(VEGF)药物起始联合地塞米松玻璃体腔植入剂(DEX)对视网膜中央静脉阻塞(CRVO)继发黄斑水肿(ME)患眼黄斑区外层视网膜结构完整性的长期影响及疗效。方法 回顾性临床研究。2015年2月至2022年8月于中部战区总医院眼科检查确诊的CRVO合并ME(CRVO-ME)患者54例54只眼纳入研究。其中,男性30例30只眼,女性24例24只眼;均为单眼患病。根据治疗方案的不同,将患者分为玻璃体腔注射DEX和抗VEGF药物联合治疗组(起始联合组)、单纯玻璃体腔注射抗VEGF药物组(单药组),分别为21、33只眼。患眼均行最佳矫正视力(BCVA)、光相干断层扫描(OCT)检查。OCT仪测量中央视网膜厚度(CRT)以及黄斑1mm区外界膜(ELM)、椭圆体带(EZ)、嵌合体带(IZ)缺失长度。起始联合组在联合治疗后经评估按需(PRN)给予抗VEGF药物或DEX治疗;单药组接受3+PRN方案治疗。首次治疗后1、6、12个月(分别记录为V1、V6、V12)以及2023年12月观察截止点或最后一次访视(记录为Vf)采用治疗前相同的设备和方法行相关检查,对比观察两组患眼基线以及V1、V6、V12、Vf时ELM、EZ、IZ缺失长度变化。组间BCVA、CRT以及不同随访时间ELM、EZ、IZ缺失长度比较采用重复测量方差分析;两组连续变量的相关分析采用Spearman秩相关检验。结果 起始联合组、单药组患者随访时间分别为(18。05±5。66)、(21。90±10。80)个月,差异无统计学意义(F=13。430,P=0。229)。与基线时比较,起始联合组、单药组患眼治疗后不同随访时间ELM、EZ、IZ缺失长度均明显改善(F=11。848、10。880、29。236),BCVA提高(F=10。541),CRT降低(F=52。278),差异均有统计学意义(P<0。001)。V1时,起始联合组、单药组EZ、IZ缺失长度分别为(344。10±413。03)、(593。33±372。96)μm和(354。71±321。75)、(604。85±385。77)μm,起始联合组EZ、IZ缺失长度改善优于单药组,差异有统计学意义(F=5。272、6。106,P=0。026、0。017);起始联合组、单药组CRT分别为(248。86±59。99)、(314。72±214。91)μm,起始联合组CRT显著低于单药组,差异有统计学意义(F=6。102,P=0。017)。V6、V12、Vf时,起始联合组、单药组ELM、EZ、IZ缺失长度以及BCVA、CRT比较,差异均无统计学意义(P>0。05)。相关性分析结果显示,起始联合组、单药组ELM、EZ、IZ与BCVA、CRT均呈正相关(P<0。001)。V6、V1 2、Vf时,起始联合组、单药组抗VEGF药物注射次数分别为(2。67±1。32)、(4。43±2。27)、(6。05±3。51)次和(4。58±0。90)、(7。33±1。93)、(11。33±6。10)次;起始联合组注射次数明显少于单药组,差异有统计学意义(F=5。150、0。646、3。433,P<0。01)。结论 起始联合组患眼BCVA、CRT改善程度与单药组近似;与单药组比较,起始联合组患眼早期EZ、IZ缺失改善更为显著,CRT下降更为明显;起始联合组较单药组接受更少的抗VEGF药物注射次数。
Long-term observation of structural integrity changes in the outer retina of macular edema with central retinal vein occlusion after initial combination therapy of anti-vascular endothelial growth factor and dexamethasone intravitreal implantation
Objective To observe the long-term effects of anti-vascular endothelial growth factor(VEGF)drug initiation combined with dexamethasone intravitreal implant(DEX)on the structural integrity of the outer macular region of the eye in patients with macular edema(ME)secondary to central retinal vein occlusion(CRVO).Methods A retrospective clinical study.From February 2018 to August 2022,54 patients diagnosed with CRVO combined with ME(CRVO-ME)in Department of Ophthalmology of Central Theater Command General Hospital were included in the study.Among them,there were 30 males and 24 females,all with monocular disease.According to different treatment regiments,patients were divided into anti-VEGF and DEX combination therapy group(initial combination group),anti-VEGF drug monotherapy group(monotherapy group)with 21 eyes and 33 eyes,respectively.Best corrected visual acuity(BCVA),optical coherence tomography(OCT)examination were performed in all eyes.The thickness of foveal retina(CRT)and the deficiency length of outer membrane(ELM),ellipsoid band(EZ)and chimaera band(IZ)in the 1 mm macular area were measured by OCT.The initiating combination group was treated with anti-VEGF agents or DEX as assessed on demand(PRN)after the combination therapy,and the monotherapy group received 3+PRN regimen.Relevant examinations were performed at 1(V1),6(V6),12(V12)months and observation cut-off or the last visit(Vf)after treatment using the same equipment before treatment.The deletion length of ELM,EZ and IZ in V1,V6,V12 and Vf after treatment were compared between the two groups.Repeated measurement ANOVA was used to compare BCVA,CRT and deletion length of ELM,EZ and IZ at different follow-up times.Spearman rank correlation test was used to analyze the correlation between the two groups of continuous variables.Results The follow-up time of patients in the initial combination group and monotherapy group was(18.05±5.66)and(21.90±10.80)months,respectively,with no statistical significance(F=13.430,P=0.229).Compared with baseline,the deletion lengths of ELM,EZ and IZ were significantly improved(F=1 1.848,10.880,29.236),BCVA was increased(F=10.541)and CRT was decreased(F=52.278)in the initial combination group and the monotherapy group at different follow-up times after treatment.The differences were statistically significant(P<0.001).At V1,EZ and IZ deletion lengths were(344.10±413.03),(593.33±372.96)μm and(354.71±321.75),(604.85±385.77)μm in the initial combination group and monotherapy group,respectively.The improvement of EZ and IZ deletion lengths in the initial combination group was better than that in the single drug group,and the difference was statistically significant(F=5.272,6.106;P=0.026,0.017).The CRT of the initial combination group and the monotherapy group were(248.86±59.99)and(314.72±214.91)μm,respectively,and the CRT of the initial combination group was significantly lower than that of the monotherapy group,with statistical significance(F=6.102,P=0.017).At V6,V12 and Vf,the deletion length of ELM,EZ and IZ and BCVA and CRT showed no statistical significance(P>0.05).Correlation analysis showed that ELM,EZ,IZ were positively correlated with BCVA and CRT in the initial combination group and monotherapy group(P<0.001).In V6,V12 and Vf,the number of anti-VEGF drug injections in the initial combination group and monotherapy group was(2.67±1.32),(4.43±2.27),(6.05±3.51),(4.58±0.90),(7.33±1.93),(11.33±6.10)times,respectively.The number of injections in the initial combination group was significantly lower than that in the monotherapy group,and the difference was statistically significant(F=5.150,0.646,3.433;P<0.001).Conclusions The improvement of BCVA and CRT in the initial combination group is similar to that in the monotherapy group.Compared with the monotherapy group,EZ and IZ deletion are improved more significantly in the initial combination group,and CRT decreased more rapidly and significantly.The initial combination group receives fewer anti-VEGF injections than the monocular group.

Central retinal vein occlusionMacular edemaDexamethasone intravitreal implantAnti-vascular endothelial growth factorCombination therapy

叶娅、黄珍、闫明、许国仁、宋艳萍

展开 >

中部战区总医院眼科,武汉 430070

视网膜中央静脉阻塞 黄斑水肿 地塞米松玻璃体腔植入剂 抗血管内皮生长因子 联合治疗

国家重点研发计划

2022YFC2502800

2024

中华眼底病杂志
中华医学会

中华眼底病杂志

CSTPCD北大核心
影响因子:0.928
ISSN:1005-1015
年,卷(期):2024.40(8)